Severe Acute Respiratory Syndrome Coronavirus-2 Induces Cytokine Storm and Inflammation During Coronavirus Disease 19: Perspectives and Possible Therapeutic Approaches.
Therapeutics
coronavirus disease
cytokine storm
inflammation
severe acute respiratory syndrome coronavirus
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
07
2020
accepted:
19
10
2020
entrez:
26
2
2021
pubmed:
27
2
2021
medline:
27
2
2021
Statut:
epublish
Résumé
The new coronavirus outbreak was first identified in Wuhan, China, in December 2019, and has turned out to be a global health emergency, affecting millions of people worldwide. Coronavirus disease 19 (COVID-19), caused by the SARS-CoV-2 virus, can manifest with flu-like symptoms and can be complicated by severe pneumonia with acute respiratory distress syndrome (ARDS); however a large percentage of infected individuals do not have symptoms but contribute to the spread of the disease. Severe acute respiratory syndrome coronavirus-2 infection has become a global public health emergency since no available treatment seems effective and it is hard to manage the several complications caused by an intense release of cytokines. This paper reviews the current options on drugs used to reduce the deadly effects of the cytokine storm.
Identifiants
pubmed: 33633566
doi: 10.3389/fphar.2020.592169
pii: 592169
pmc: PMC7902081
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
592169Informations de copyright
Copyright © 2020 Mannino, Bitto and Irrera.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Expert Rev Respir Med. 2021 Feb;15(2):257-265
pubmed: 32941741
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Int J Antimicrob Agents. 2020 Aug;56(2):106080
pubmed: 32634603
J Med Virol. 2006 Jan;78(1):1-8
pubmed: 16299724
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
Virol J. 2005 Aug 22;2:69
pubmed: 16115318
Arch Med Res. 2020 Oct;51(7):728-730
pubmed: 32532523
J Virol. 2010 Jan;84(2):1198-205
pubmed: 19864379
Int J Mol Sci. 2016 May 05;17(5):
pubmed: 27164085
Lancet. 2020 May 30;395(10238):1695-1704
pubmed: 32401715
Microbes Infect. 2020 May - Jun;22(4-5):226-229
pubmed: 32361001
BioDrugs. 2019 Feb;33(1):45-60
pubmed: 30560413
Cell Host Microbe. 2016 Feb 10;19(2):181-93
pubmed: 26867177
Biochim Biophys Acta. 2013 Jun;1830(6):3670-95
pubmed: 23428572
Eur J Immunol. 2010 Mar;40(3):616-9
pubmed: 20201014
Virol Sin. 2020 Jun;35(3):266-271
pubmed: 32125642
Cell. 2010 Mar 19;140(6):805-20
pubmed: 20303872
Biochem Biophys Res Commun. 2009 Oct 30;388(4):621-5
pubmed: 19686699
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830861
Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4016-4026
pubmed: 32329877
Lancet. 2020 Feb 15;395(10223):e30-e31
pubmed: 32032529
Nat Immunol. 2015 Apr;16(4):343-53
pubmed: 25789684
J Med Virol. 2020 Nov;92(11):2314-2315
pubmed: 32391920
Bing Du Xue Bao. 2011 Mar;27(2):108-16
pubmed: 21528534
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Viruses. 2019 Jan 09;11(1):
pubmed: 30634407
Front Mol Biosci. 2020 Aug 11;7:196
pubmed: 32850977
Cell Res. 2013 Feb;23(2):300-2
pubmed: 23208422
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
Life Sci. 2020 Sep 15;257:118075
pubmed: 32653522
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Arch Med Res. 2020 Aug;51(6):595-597
pubmed: 32482373
Nat Rev Drug Discov. 2020 Mar;19(3):149-150
pubmed: 32127666
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):327-331
pubmed: 32171193
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Immunopharmacology. 2000 Sep;49(3):295-306
pubmed: 10996027
Lancet Infect Dis. 2020 Apr;20(4):400-402
pubmed: 32113509
Lancet Rheumatol. 2020 Jul;2(7):e393-e400
pubmed: 32835245
Bratisl Lek Listy. 2020;121(10):705-711
pubmed: 32955901
Lancet. 2020 May 22;:
pubmed: 32450107
Antiviral Res. 2017 Jan;137:49-57
pubmed: 27847245
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Crit Care Med. 2016 Feb;44(2):275-81
pubmed: 26584195
Science. 2005 Sep 16;309(5742):1864-8
pubmed: 16166518
Arch Med Res. 2020 Aug;51(6):585-586
pubmed: 32439198
Biotechnol Lett. 2012 May;34(5):831-8
pubmed: 22350287
IUBMB Life. 2020 Nov;72(11):2331-2354
pubmed: 32936531
Mol Cell. 2002 Aug;10(2):417-26
pubmed: 12191486
Front Med. 2020 Dec;14(6):760-775
pubmed: 32926319
Nat Rev Microbiol. 2020 Mar;18(3):123
pubmed: 31988490
Nat Rev Immunol. 2014 Dec;14(12):821-6
pubmed: 25359439
Cell Biochem Biophys. 2014 Nov;70(2):1305-9
pubmed: 24938899
Annu Rev Microbiol. 2019 Sep 8;73:529-557
pubmed: 31226023
Adv Rheumatol. 2020 Sep 22;60(1):50
pubmed: 32962761
PLoS Pathog. 2018 Aug 13;14(8):e1007236
pubmed: 30102747
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Trends Microbiol. 2013 Oct;21(10):544-55
pubmed: 23770275
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Antivir Chem Chemother. 2018 Jan-Dec;26:2040206618764483
pubmed: 29562753
Virus Res. 2008 Sep;136(1-2):8-15
pubmed: 18554741
J Altern Complement Med. 2004 Dec;10(6):1041-51
pubmed: 15674000
Pharm Biol. 2012 Apr;50(4):401-6
pubmed: 22136493
Eur J Intern Med. 2020 Jun;76:14-20
pubmed: 32336612
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
Antiviral Res. 2018 Jan;149:58-74
pubmed: 29128390
Lancet Infect Dis. 2006 Feb;6(2):67-9
pubmed: 16439323
Microbes Infect. 2013 Feb;15(2):88-95
pubmed: 23123977